Description

Bydureon BCise is a once‑weekly, single‑dose autoinjector of extended‑release exenatide for adults with type 2 diabetes; the recommended dose is 2 mg subcutaneously once weekly, and it carries a boxed warning about thyroid C‑cell tumors and contraindications for patients with a personal or family history of medullary thyroid carcinoma or MEN 2.

What Bydureon BCise is

Bydureon BCise contains exenatide extended‑release formulated as a ready‑to‑use autoinjector that delivers sustained GLP‑1 receptor agonist activity over seven days. It is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes.

How it works

Bydureon BCise mimics the incretin hormone GLP‑1 to stimulate glucose‑dependent insulin secretion, suppress inappropriate glucagon release, and slow gastric emptying, which together reduce fasting and postprandial blood glucose and often support modest weight loss in patients with type 2 diabetes.

Dosing and administration

• Standard dose: 2 mg once weekly by subcutaneous injection into the abdomen, thigh, or upper arm; the dose can be given at any time of day, with or without meals.
• Autoinjector convenience: Bydureon BCise is supplied as a single‑use autoinjector designed to simplify preparation and injection for patients and caregivers.
• Switching guidance: discontinue immediate‑release exenatide before initiating Bydureon BCise; patients switching from other exenatide products may experience transient glucose changes. Contact Us

Safety, contraindications, and side effects

• Boxed warning: rodent studies showed thyroid C‑cell tumors; do not use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Common adverse effects: nausea, vomiting, diarrhea, and injection‑site reactions; these are usually transient and lessen over time.
• Serious risks: pancreatitis and renal impairment have been reported; seek urgent care for severe abdominal pain or sudden changes in kidney function.

Patient tips and practical guidance

• Rotate injection sites to reduce local reactions and follow the autoinjector instructions for use.
• Storage: follow the product leaflet for refrigeration and in‑use shelf life; do not use if the autoinjector is damaged or expired.
• When to contact a clinician: persistent severe GI symptoms, signs of pancreatitis, unexplained renal changes, or symptoms of allergic reaction require prompt medical attention.